{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:17:45Z","timestamp":1769573865629,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40266-019-00655-y","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T03:05:22Z","timestamp":1553828722000},"page":"647-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pimavanserin for Psychosis in Parkinson\u2019s Disease-Related Disorders: A Retrospective Chart Review"],"prefix":"10.1007","volume":"36","author":[{"given":"Jessie","family":"Sellers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Ryan","family":"Darby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Farooque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel O.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"issue":"8","key":"655_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson\u2019s disease: a review. Drugs Aging. 2008;25(8):665\u201382.","journal-title":"Drugs Aging"},{"issue":"6","key":"655_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/mds.22839","volume":"25","author":"G F\u00e9nelon","year":"2010","unstructured":"F\u00e9nelon G, Soulas T, Zenasni F, De Langavant LC. The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):755\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.22839\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"5","key":"655_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528\u201336.","journal-title":"Int J Geriatr Psychiatry"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285610389656","volume":"3","author":"P Shotbolt","year":"2010","unstructured":"Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2010;3:339\u201350.","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"655_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340(10):757\u201363.","journal-title":"N Engl J Med"},{"issue":"5","key":"655_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"655_CR7","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.16r11119","author":"MV Mathis","year":"2017","unstructured":"Mathis MV, Muoio BM, Andreason P, et al. The US Food and Drug Administration\u2019s perspective on the new antipsychotic pimavanserin. J Clin Psychiatry. 2017. \n                    https:\/\/doi.org\/10.4088\/jcp.16r11119\n                    \n                  .","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"655_CR8","doi-asserted-by":"publisher","first-page":"e00639","DOI":"10.1002\/brb3.639","volume":"7","author":"M Yuan","year":"2017","unstructured":"Yuan M, Sperry L, Malhado-Chang N, et al. Atypical antipsychotic therapy in Parkinson\u2019s disease psychosis: a retrospective study. Brain Behav. 2017;7(6):e00639. \n                    https:\/\/doi.org\/10.1002\/brb3.639\n                    \n                  .","journal-title":"Brain Behav"},{"issue":"4","key":"655_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/WNF.0000000000000219","volume":"40","author":"JH Friedman","year":"2017","unstructured":"Friedman JH. A retrospective study of pimavanserin use in a movement disorders clinic. Clin Neuropharmacol. 2017;40(4):157\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"655_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/00325481.2018.1411161","volume":"130","author":"N Hermanowicz","year":"2018","unstructured":"Hermanowicz N. Delusional misidentification in Parkinson\u2019s disease: report of two cases and a review. Postgrad Med. 2018;130(2):280\u20133.","journal-title":"Postgrad Med"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000006396","volume":"00","author":"GM Moreno","year":"2018","unstructured":"Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. Neurology. 2018;00:1\u20133. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000006396\n                    \n                  .","journal-title":"Neurology"},{"issue":"2","key":"655_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"9916","key":"655_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340.","journal-title":"Lancet"},{"issue":"1","key":"655_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1440-1819.2011.02291.x","volume":"66","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Yousuf MS, Naz S, Qaaty N. Prevalence and relation of dementia to various factors in Parkinson\u2019s disease. Psychiatry Clin Neurosci. 2012;66(1):64\u20138. \n                    https:\/\/doi.org\/10.1111\/j.1440-1819.2011.02291.x\n                    \n                  .","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"655_CR15","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1001\/jamaneurol.2013.3579","volume":"70","author":"R Savica","year":"2013","unstructured":"Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396\u2013402. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2013.3579\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"655_CR16","unstructured":"(2013) Diagnostic and statistical manual of mental disorders:\u00a0DSM-5. American Psychiatric Publishing, Arlington."},{"issue":"2","key":"655_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","volume":"59","author":"SR Beach","year":"2018","unstructured":"Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics. 2018;59(2):105\u201322. \n                    https:\/\/doi.org\/10.1016\/j.psym.2017.10.009\n                    \n                  .","journal-title":"Psychosomatics"},{"issue":"3","key":"655_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hbm.23080","volume":"37","author":"C Gasca-Salas","year":"2016","unstructured":"Gasca-Salas C, Clavero P, Garc\u00eda-Garc\u00eda D, Obeso JA, Rodr\u00edguez-Oroz MC. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson\u2019s disease patients with mild cognitive impairment. Hum Brain Mapp. 2016;37(3):968\u201377.","journal-title":"Hum Brain Mapp"},{"issue":"3","key":"655_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S\u00f8rensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387\u201392.","journal-title":"Arch Neurol"},{"issue":"14","key":"655_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","volume":"83","author":"JBM Anang","year":"2014","unstructured":"Anang JBM, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology. 2014;83(14):1253\u201360.","journal-title":"Neurology"},{"issue":"18","key":"655_CR21","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1212\/WNL.0b013e3181bf992f","volume":"73","author":"EY Uc","year":"2009","unstructured":"Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009;73(18):1469\u201377.","journal-title":"Neurology"},{"issue":"1","key":"655_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jnnp-2011-300043","volume":"83","author":"L Morgante","year":"2012","unstructured":"Morgante L, Colosimo C, Antonini A, et al. Psychosis associated to Parkinson\u2019s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83(1):76\u201382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"655_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/jnnp.2009.179655","volume":"81","author":"N Ibarretxe-Bilbao","year":"2010","unstructured":"Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson\u2019s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010;81(6):650\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"655_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000100850","volume":"23","author":"B Ramirez-Ruiz","year":"2007","unstructured":"Ramirez-Ruiz B, Junque C, Marti M-J, Valldeoriola F, Tolosa E. Cognitive changes in Parkinson\u2019s disease patients with visual hallucinations. Dement Geriatr Cogn Disord. 2007;23(5):281\u20138.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"655_CR25","unstructured":"Ellis B, Hicken M (2018) FDA worried drug was risky; now reports of deaths spark concern. CNN. \n                    https:\/\/www.cnn.com\/2018\/04\/09\/health\/parkinsons-drug-nuplazid-invs\/index.html\n                    \n                  . Accessed 18 Aug 2018."},{"issue":"2","key":"655_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/brain\/aww288","volume":"140","author":"RR Darby","year":"2017","unstructured":"Darby RR, Laganiere S, Pascual-Leone A, Prasad S, Fox MD. Finding the imposter: brain connectivity of lesions causing delusional misidentifications. Brain. 2017;140(2):497\u2013507.","journal-title":"Brain"},{"issue":"3","key":"655_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1176\/appi.neuropsych.15100376","volume":"28","author":"R Darby","year":"2016","unstructured":"Darby R, Prasad S. Lesion-related delusional misidentification syndromes: a comprehensive review of reported cases. J Neuropsychiatry Clin Neurosci. 2016;28(3):217\u201322.","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00655-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:37:50Z","timestamp":1585355870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00655-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"assertion":[{"value":"29 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved through the Vanderbilt University Medical Center (VUMC) Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the conduct or reporting of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jessie Sellers has received research support and personal fees for speaker bureau participation from Teva Neuroscience. Dr. Darby is supported by grants from the Alzheimer\u2019s Association, Brightfocus Foundation, and Vanderbilt Institute for Clinical and Translational Research. Daniel O. Claassen receives research support from the National Institute of Neurological Disorders and Stroke (NINDS), Griffin Foundation, Michael J. Fox Foundation, and Huntington\u2019s Disease Society of America (HDSA), and pharmaceutical grant support from AbbVie, Acadia, Biogen, BMS, Cerecour, Eli Lilly, Lundbeck, Jazz Pharmaceuticals, Teva Neuroscience, Wave Life Sciences, and Vaccinex. He has received personal fees for consulting and advisory board participation from Acadia, Adamas, Lundbeck, Neurocrine, and Teva Neuroscience. Given a potential conflict with Acadia (makers of pimavanserin), he excluded himself from data acquisition and data analysis, but provided direction on project design, and critical review and revision of the manuscript. Alma Farooque has no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}